COCP Latest Press Releases

-- May 26, 2026 --

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza Globe Newswire 8:00 AM

-- May 15, 2026 --

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- April 30, 2026 --

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection Globe Newswire 4:05 PM

-- April 2, 2026 --

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive Globe Newswire 8:00 AM

-- March 31, 2026 --

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Globe Newswire 8:00 AM

-- March 9, 2026 --

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment Globe Newswire 8:00 AM

-- February 19, 2026 --

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software